-
Global Neutropenia Biologic Drug Treatment Market Forecast 2024-2033 – Market Size, Drivers, Trends, And Competitors
28 Mar 2024 13:00 GMT
… .
Neutropenia Biologic Drug Treatment Market Segments
• By Drug Type: Filgrastim, Pegfilgrastim, Lenograstim … equipment-global-market-report
Pharmaceutical API Manufacturing Global Market … /report/pharmaceutical-api-manufacturing-global-market- …
-
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
17 Apr 2024 14:00 GMT
… trial that supported the U.S. Food and Drug Administration (FDA) … from the Phase 3 Trials
Authors: Edmund K. Waller … dose. Use analgesic medication and local treatments post-dose, as … APHEXDA in conjunction with filgrastim increases circulating leukocytes as …
-
BioLineRx doses first subject in Phase II pancreatic cancer trial
29 Feb 2024 13:13 GMT
… CheMo4METPANC clinical trial evaluating the CXCR4 inhibitor motixafortide for the treatment of … from the US Food and Drug Administration (FDA) in September last year … indicated for use along with filgrastim for mobilisation of hematopoietic stem …
-
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
29 Feb 2024 03:53 GMT
… urgent need for new treatment approaches," said … Drug Administration (FDA) in September 2023, in combination with filgrastim ( … pipeline of investigational medicines for patients with … preclinical studies, clinical trials, and other therapeutic candidate …
-
BioLineRx doses first patient in randomized phase 2 combination trial to evaluate CXCR4 inhibitor, motixafortide in pancreatic cancer
01 Mar 2024 13:07 GMT
… PDAC). The investigator-initiated trial is being conducted in … urgent need for new treatment approaches," said Philip … US FDA in September 2023, in combination with filgrastim (G … randomized, investigator-initiated clinical trial in first line metastatic …
-
Human medicines European public assessment report (EPAR): Pelmeg, pegfilgrastim, Date of authorisation: 20/11/2018, Revision: 8, Status: Authorised
19 Feb 2024 15:29 GMT
… factor (G-CSF). Filgrastim works by encouraging the … neutropenia.
Filgrastim has been available in other medicines in the … of years. In Pelmeg, filgrastim has been ‘pegylated’ (attached … removal of filgrastim from the body, allowing the medicine to …
-
Biosimilars Would Reduce Health Care Costs But Are Yet Poorly Known – Patient Survey Study Among Biological Medicine Users
03 Feb 2024 14:20 GMT
… treatment is … medicines containing the following active substances: adalimumab, etanercept, pegfilgrastim, or filgrastim … doctors prescribing biological medicines.13 In 2020, a “Dear Doctor” letter acknowledged those doctors … säästöjä [Drug reimbursements …
-
Filgrastim Market is set to Reach US$ 745.1 million at a CAGR of 3.2% from the forecast period 2023 to 2031 | Growth Plus Reports
19 Jan 2024 08:21 GMT
… Growth Plus Reports, the global Filgrastim Treatment Market is expected to clock …
Historical Year
2021
Segments Covered
Drug Type, Indication, Distribution Channel, … proud members of EPhMRA (European Pharmaceutical Marketing Research Association). Growth Plus …
-
Accord BioPharma, Inc. Announces U.S. FDA Acceptance of Biologics License Application for Proposed STELARA® Biosimilar DMB-3115
05 Jan 2024 00:59 GMT
… drug developed by Janssen Biotech, Inc. and approved for the treatment … rights granted to Intas Pharmaceuticals through a partnership … multi-regional clinical trials in patients with … FDA for biosimilar versions of trastuzumab, pegfilgrastim, and filgrastim. …
-
FDA Accepts Accord BioPharma's BLA for Proposed Ustekinumab Biosimilar DMB-3115
04 Jan 2024 18:41 GMT
… the US Food and Drug Administration (FDA) accepting its Biologics … accessible avenue for the treatment of conditions associated … rights granted to Intas Pharmaceuticals in 2021, showcases … trastuzumab, pegfilgrastim, and filgrastim, signaling a strategic move …